It seems possible, and maybe even expected, that FDA will approve an interchangeable biosimilar before guidance becomes available on the subject.
That is not an ideal scenario for industry, but it also is not unprecedented for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?